On May 15, 2025, the Company entered into a lease termination agreement with HGIT Historic Decatur LP to terminate the Company’s San Diego, California office space.
Reciprocal relationship from OGEN graph: we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opport…
and development costs are expensed as incurred. The Company incurred research and development expense of $ 29,681 and $ 46,004 , and $ 206,161 and $ 679,183 for the three and nine months ended Septem…
Sigyn Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SIGY-DEBT
Debt stack $2.8M
90%
Market cache reports total debt of $2.8M.
SIGY-DEBT-12530
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
SIGY-DEBT-12529
Warrants outstanding: 559839
90%
xbrl warrant detail from xbrl 2024-12-31.
Sigyn Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sigyn Therapeutics, Inc..
Sigyn Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Sigyn Therapeutics, Inc..
Sigyn Therapeutics, Inc. Extended Supply Chain Network
